The US FDA and the European EMA recently approved two anti-CD19 CAR-T-cell products, YESCARTA* (Axicabtagene Ciloleucel) and KYMRIAH* (Tisagenlecleucel), for the treatment of patients with CD19-positive malignancies, such as refractory diffuse large B cell lymphoma (DLBCL) or relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in children and young adults [94,95]. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.